Title:Dual Targeting Anti-Osteoporotic Therapy Through Potential Nanotherapeutic
Approaches
Volume: 10
Issue: 5
Author(s): Sagar Salave, Dhwani Rana and Derajram Benival*
Affiliation:
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad,
India
Keywords:
Anabolic agent, osteoporosis, antiresorptive, dual drug delivery, nanotechnology, targeted drug delivery.
Abstract: Osteoporosis is characterised by a major public health burden, particularly taking into
account the ageing global population. Therapeutic modalities for osteoporosis are categorised on
the basis of their effect on bone remodeling: antiresorptive and anabolic agents. Anabolic drugs are
favoured as they promote the formation of new bone, whereas antiresorptive drugs terminate the
further deterioration of bone. Non-specific delivery of anabolic agents results in prolonged kidney
exposure causing malignant hypercalcemia, whereas antiresorptive agents and bisphosphonates
may produce osteonecrosis of the jaw. Several clinical trials have been reported for combinational
therapy of anabolic agents and antiresorptive agents for osteoporosis. However, none of them have
proven their cumulative effects in the treatment of disease. The present work emphasizes a dualtargeting
drug delivery approach comprising of bone anabolic and antiresorptive agents that would
simultaneously deliver the therapeutic agents to both the zones of bone. The anticipated pioneering
delivery approach will intensify the explicit interaction between the therapeutic agent and bone
surfaces separately without developing severe adverse effects and improve osteoporotic therapy
effectively compared to non-targeted drug delivery.
